Further studies showed that the full potency of CCL21-mediated anti-tumor response required the induction of IFN-γ, MIG/CXCL9 and IP-10/CXCL10 in concert, as neutralization or depletion of any one of these cytokines led to a decrease in the frequency of CXCR3+ve T cells and CD11c+ve DC in the tumor [8,9]. The gene discussed is CCL21; the disease is neoplasm.